#United States #XPOVIO #Newton #Karyopharm Therapeutics #NEXPOVIO

Karyopharm Therapeutics Announces New Inducement Grants

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leading commercial-stage pharmaceutical company, announced an important step in its employee recruitment strategy on October 1, 2025. The company granted a total of 333 restricted stock units (RSUs) to a newly hired employee, effective as of September 30, 2025. This initiative is part of Karyopharm's 2022 Inducement Stock Incentive Plan, which was amended to comply with specific provisions of Nasdaq Listing Rule 5635(c)(4).

The newly granted RSUs are structured to vest over a three-year period. Notably, one-third of these shares will vest on each anniversary of the grant date, contingent upon the employee maintaining their position with Karyopharm throughout the vesting duration. This approach reflects Karyopharm's commitment to attracting and retaining top talent in the competitive pharmaceutical landscape, particularly in the area of pioneering cancer therapies.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is dedicated to advancing innovative cancer treatments, firmly driven by a respect for the resilience of cancer patients. The company has carved out a niche in the industry by focusing on oral compounds that tackle nuclear export dysregulation—a critical factor in the development of many cancers.

Among its flagship products is XPOVIO® (selinexor), a first-in-class oral exportin 1 (XPO1) inhibitor that has obtained regulatory approval in the United States for multiple oncology indications. The drug is marketed by Karyopharm and has seen success in various territories worldwide, including Europe and the United Kingdom, where it is known as NEXPOVIO®. Karyopharm's reputation in the pharmaceutical industry is anchored not only in its innovative treatments but also in its responses to unmet medical needs across multiple cancer categories, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).

Karyopharm’s commitment to understanding the complexities of cancer has made it a leader in the field, constantly focusing on research and development to bring forward new therapeutic options for patients facing difficult diagnoses. The company's pipeline demonstrates a clear focus on addressing high unmet needs in the oncology sector.

To stay informed about the latest developments in Karyopharm's endeavors and their impactful work towards innovative cancer therapies, interested parties can visit Karyopharm's official website or connect with them on professional platforms like LinkedIn and X, where updates are regularly shared.

Conclusion

As Karyopharm Therapeutics continues to overcome industry challenges and expand its workforce, the recent issuance of RSUs to a new employee marks a pivotal moment for the company. Not only does this reflect a strategic move to enhance talent acquisition but also underscores the organization's ongoing mission to provide hope and health to cancer patients worldwide. Such initiatives coupled with their robust product offerings position Karyopharm therapeutics as a formidable player in the life sciences arena, dedicated to revolutionary approaches against cancer.

XPOVIO® and NEXPOVIO® continue to be guiding forces in Karyopharm's journey to redefining cancer treatment paradigms.